Skip to main content

Advertisement

SpringerLink
Log in

Validation of brain tumour imaging with p-[123I]iodo-l-phenylalanine and SPECT

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aims of this prospective study were to validate single-photon emission computed tomography (SPECT) with p-[123I]iodo-l-phenylalanine (IPA) in brain tumours and to evaluate its potential for the characterisation of indeterminate brain lesions.

Methods

In 45 patients with indeterminate brain lesions or suspected progression of glioma, amino acid uptake was studied using IPA-SPECT and compared with the final diagnosis established by biopsy or serial imaging. After image fusion of IPA-SPECT and magnetic resonance imaging, the presence of tumour was visually determined by two independent observers. IPA uptake was quantified as the ratio between maximum uptake in the suspicious lesion and mean uptake in unaffected brain.

Results

Primary brain tumours were present in 35 cases (12 low-grade and 23 high-grade gliomas). Non-neoplastic brain lesions were confirmed in seven cases (three dysplasias, three inflammatory lesions, one lesion after effective therapy). Visual analysis showed a high concordance between the two observers (kappa=0.90, p<0.001), with sensitivity and specificity of 86% and 100% for the discrimination of primary brain tumours and non-neoplastic lesions. At 30 min p.i., IPA uptake in primary brain tumours was higher than that in non-neoplastic lesions (1.70±0.36 vs 1.14±0.18, p<0.05). Brain metastases showed no increased uptake (1.13±0.22, n=3). The persistent retention of IPA in low-grade gliomas without disruption of the blood–brain barrier was visualised up to 24 h p.i. Low-grade and high-grade gliomas showed equivalent IPA uptake (1.72±0.37 vs 1.67±0.36 at 30 min, p=0.745).

Conclusion

IPA shows long and specific retention in gliomas. IPA is a promising and safe radiopharmaceutical for the visualisation of gliomas and the characterisation of indeterminate brain lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114–23

    Article  CAS  PubMed  Google Scholar 

  2. Bénard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003;33:148–62

    Article  PubMed  Google Scholar 

  3. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678–87

    Article  PubMed  Google Scholar 

  4. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, et al. O-(2-[18F]fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542–9

    CAS  PubMed  Google Scholar 

  5. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464–70

    PubMed  Google Scholar 

  6. Biersack HJ, Coenen HH, Stöcklin G, Reichmann K, Bockisch A, Oehr P, et al. Imaging of brain tumors with l-3-[123I]iodo-alpha-methyl tyrosine and SPECT. J Nucl Med 1989;30:110–2

    CAS  PubMed  Google Scholar 

  7. Grosu AL, Feldmann H, Dick S, Dzewas B, Nieder C, Gumprecht H, et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 2002;54:842–54

    Article  PubMed  Google Scholar 

  8. Weckesser M, Griessmeier M, Schmidt D, Sonnenberg F, Ziemons K, Kemna L, et al. Iodine-123 alpha-methyl tyrosine single-photon emission tomography of cerebral gliomas: standardised evaluation of tumour uptake and extent. Eur J Nucl Med 1998;25:150–6

    Article  CAS  PubMed  Google Scholar 

  9. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996;23:1345–53

    Article  CAS  PubMed  Google Scholar 

  10. Matheja P, Rickert C, Weckesser M, Palkovic S, Lottgen J, Riemann B, et al. Sequential scintigraphic strategy for the differentiation of brain tumours. Eur J Nucl Med 2000;27:550–8

    Article  CAS  PubMed  Google Scholar 

  11. Woesler B, Kuwert T, Morgenroth C, Matheja P, Palkovic S, Schäfers M, et al. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med 1997;24:428–34

    CAS  PubMed  Google Scholar 

  12. Riemann B, Papke K, Hoess N, Kuwert T, Weckesser M, Matheja P, et al. Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-l-alpha-methyltyrosine SPECT. Radiology 2002;225:567–74

    PubMed  Google Scholar 

  13. Weber WA, Dick S, Reidl G, Dzewas B, Busch R, Feldmann HJ, et al. Correlation between postoperative 3-[123I]iodo-l-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144–50

    CAS  PubMed  Google Scholar 

  14. Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF, et al. Clinical value of iodine-123-alpha-methyl-l-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002;20:396–404

    Google Scholar 

  15. Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, et al. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 1998;39:23–7

    CAS  PubMed  Google Scholar 

  16. Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, et al. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 1999;26:144–51

    Article  CAS  PubMed  Google Scholar 

  17. Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, et al. SPECT studies of brain tumors with l-3-[123I]iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med 1990;31:281–6

    CAS  PubMed  Google Scholar 

  18. Samnick S, Richter S, Romeike BF, Heimann A, Feiden W, Kempski O, et al. Investigation of iodine-123-labelled amino acid derivatives for imaging cerebral gliomas: uptake in human glioma cells and evaluation in stereotactically implanted C6 glioma rats. Eur J Nucl Med 2000;27:1543–51

    Article  CAS  PubMed  Google Scholar 

  19. Samnick S, Schaefer A, Siebert S, Richter S, Vollmar B, Kirsch CM. Preparation and investigation of tumor affinity, uptake kinetic and transport mechanism of iodine-123-labelled amino acid derivatives in human pancreatic carcinoma and glioblastoma cells. Nucl Med Biol 2001;28:13–23

    Article  CAS  PubMed  Google Scholar 

  20. Samnick S, Hellwig D, Bader JB, Romeike BF, Moringlane JR, Feiden W, et al. Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-l-phenylalanine for routine brain tumour imaging. Nucl Med Commun 2002;23:121–30

    Article  CAS  PubMed  Google Scholar 

  21. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994;13:601–9

    Article  Google Scholar 

  22. Chang LT. A method for attenuation correction in radionuclide computer tomography. IEEE Trans Nucl Sci 1978;26:2780–9

    Google Scholar 

  23. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187–98

    Article  CAS  PubMed  Google Scholar 

  24. Thurfjell L, Lau YH, Andersson JL, Hutton BF. Improved efficiency for MRI-SPET registration based on mutual information. Eur J Nucl Med 2000;27:847–56

    Article  CAS  PubMed  Google Scholar 

  25. Langen KJ, Broer S. Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT. J Nucl Med 2004;45:1435–6

    CAS  PubMed  Google Scholar 

  26. Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997;38:802–8

    CAS  PubMed  Google Scholar 

  27. Schmidt D, Gottwald U, Langen KJ, Weber F, Hertel A, Floeth F, et al. 3-[123I]Iodo-alpha-methyl-l-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. Eur J Nucl Med 2001;28:855–61

    Article  CAS  PubMed  Google Scholar 

  28. Samnick S, Romeike BF, Kubuschok B, Hellwig D, Amon M, Feiden W, et al. p-[123I]iodo-l-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma. Eur J Nucl Med Mol Imaging 2004;31:532–41

    Article  PubMed  Google Scholar 

  29. Weckesser M, Matheja P, Rickert CH, Strater R, Palkovic S, Lottgen J, et al. High uptake of l-3-[123I]iodo-alpha-methyl tyrosine in pilocytic astrocytomas. Eur J Nucl Med 2001;28:273–81

    Article  CAS  PubMed  Google Scholar 

  30. Lahoutte T, Mertens J, Caveliers V, Franken PR, Everaert H, Bossuyt A. Comparative biodistribution of iodinated amino acids in rats: selection of the optimal analog for oncologic imaging outside the brain. J Nucl Med 2003;44:1489–94

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the “Deutsche Krebshilfe” by Grant 70-3024-He-1. We thank the technologists of the Department of Nuclear Medicine at the Saarland University Medical Center for their valuable technical assistance.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Saarland University Medical Center, 66421, Homburg/Saar, Germany

    Dirk Hellwig, Nadja Sell, Andrea Schaefer, Carl-Martin Kirsch & Samuel Samnick

  2. Department of Neurosurgery, Saarland University Medical Center, 66421, Homburg/Saar, Germany

    Ralf Ketter & Jean R. Moringlane

  3. Institute of Neuropathology, Saarland University Medical Center, 66421, Homburg/Saar, Germany

    Bernd F. M. Romeike

Authors
  1. Dirk Hellwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf Ketter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernd F. M. Romeike
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nadja Sell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean R. Moringlane
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carl-Martin Kirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Samuel Samnick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Hellwig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hellwig, D., Ketter, R., Romeike, B.F.M. et al. Validation of brain tumour imaging with p-[123I]iodo-l-phenylalanine and SPECT. Eur J Nucl Med Mol Imaging 32, 1041–1049 (2005). https://doi.org/10.1007/s00259-005-1807-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1807-y

Keywords

Search

Navigation